Finally, we assessed the impact of ibrutinib, which is a clinically approved BCR inhibitor, on mitochondrial respiration rates and plasma CCL3/CCL4 levels from CLL patients on ibrutinib treatment. This evidence concerns the gene CCL4 and B-cell chronic lymphocytic leukemia.